Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: GILD stock price vs ECL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ECL's multiple
Needs ECL P/E.
Implied fair value · at GILD's multiple
Needs GILD P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ECOLAB INC. · implied price per share
Bear
$44.93
Base
$57.49
Bull
$73.86
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
GILD vs ABBV
AMGEN INC
GILD vs AMGN
BRISTOL MYERS SQUIBB CO
GILD vs BMY
Merck & Co., Inc.
GILD vs MRK
PFIZER INC
GILD vs PFE
REGENERON PHARMACEUTICALS, INC.
GILD vs REGN
Procter & Gamble Company
GILD vs PG
COLGATE PALMOLIVE CO
GILD vs CL
CLOROX CO /DE/
GILD vs CLX
KIMBERLY CLARK CORP
GILD vs KMB
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe GILD can sustain its current high margins and ROIC while the market rerates it closer to ECL earnings multiples, then favor GILD because it trades at 19.2x P/E versus ECL's 36.3x despite stronger profitability; if you require fuller cash-flow and insolvency evidence, wait because FCF margin and Altman Z-Score are unavailable.
GILD appears cheap versus ECL on both earnings and enterprise-value multiples, with a P/E of 19.2x versus ECL's 36.3x and EV/EBITDA of 12.7x versus 19.9x. The implied price of $246.05 sits well above the current price of $130.28, above the historical band midpoint and near the top of ECL-implied range.
Supporting Metrics
